CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 223 enrolled
Drug / intervention
Rizatriptan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02447991
NCT02447991Phase 3Completed

A Phase II/III Trial on Rizatriptan for Vestibular Migraine

Robert W. Baloh·interventional·Posted May 19, 2015·Updated Nov 4, 2021

In Brief

A Phase 3 clinical trial evaluating Rizatriptan and Placebo for Vestibular Migraine and Migrainous Vertigo. Completed, enrolled 223 participants across 3 sites.

Detailed Summary

Suffering from dizzy spells and migraine headaches? Vestibular Migraine (VM), a newly recognized type of migraine that causes bouts of dizziness. University of California, Los Angeles (UCLA) and The Mayo Clinic is seeking people with VM to participate in a research study. The purpose of this study is to look at the natural history of VM and learn more about common symptoms. Investigators also want to learn the effects, both positive and negative, of the commonly used migraine drug, rizatriptan, when it is used for spells of dizziness in people with VM. Patients may be eligible to participate if: * Patients are between the ages of 18 \& 65 * Patients have a history of vestibular migraine * Patients are able to maintain a vestibular symptom diary The study includes 3 visits with compensation. All participants must complete questionnaires on dizziness, headache symptoms, general health and well-being, mental health, and a questionnaire on patient's satisfaction with study medication.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 19, 2015
Enrollment StartDec 1, 2014
Primary CompletionJul 31, 2020
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 11.1 years ago

Interventions

Rizatriptandrug

During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.

Placebodrug

During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.